Insmed's first commercial product, ARIKAYCE ® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium ...

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

If you have Mycobacterium avium complex (MAC) lung disease, your doctor may suggest treatment with Arikayce. It’s a prescription drug used together with other drugs to treat MAC lung disease that’s ...

Dear Doctors: I suffered extensive fatigue that I had attributed to a COVID-19 infection. Then a lung culture found something called mycobacterium avium complex. Would you kindly consider discussing ...

Concerns of lower-than-expected efficacy, which prompted AN2 Therapeutics Inc. to pause enrollment in the phase III portion of the phase II/III trial earlier this year, turned out to be well-founded, ...

Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on ...

Mycobacterium avium complex (MAC) lung disease is a rare and serious disorder that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms ...